RxDoctor Payments Data

Gertrude Gboloo, MD

Family Medicine · Gonzales, LANPI 1740491208

Payments from drug & device makers

$8,310in general payments, 2019–2025

Across 454 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Abbott$739
  • GSK$698
  • AstraZeneca$624
  • Lilly USA, LLC$547
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$505
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$8,25099%
  • Education$300%
  • Other$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,310 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$22,017
Medicare patients
57
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide137$177,081
MounjaroTirzepatide108$118,176
LinzessLinaclotide100$75,481
JardianceEmpagliflozin52$73,181
TrulicityDulaglutide42$57,807
FarxigaDapagliflozin Propanediol37$51,273
VraylarCariprazine Hcl32$49,180
Invega SustennaPaliperidone Palmitate14$46,520
JanuviaSitagliptin Phosphate31$38,110
Budesonide ErBudesonide15$34,439
RybelsusSemaglutide16$30,247
EliquisApixaban32$21,895
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,126
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,953
Tresiba Flextouch U-200Insulin Degludec11$9,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$310$207,328153 claims
Lilly USA, LLCMounjaro, Trulicity$547$175,983150 claims
AbbVieLinzess, Vraylar$1,738$124,661132 claims
Boehringer IngelheimJardiance$258$73,18152 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$624$67,80965 claims
Johnson & JohnsonInvega Sustenna$120$46,52014 claims
MerckJanuvia$63$38,11031 claims
PfizerEliquis$378$21,89532 claims
GSKTrelegy Ellipta$698$19,12628 claims
Astellas Pharma US IncMyrbetriq$31$6,99913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Gonzales

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →